3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Neuroendocrine Tumors
3
Thymus Neoplasms
1
Rhabdomyosarcoma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Cyclophosphamide
31
Rituximab
28
Biopsy
23
Specimen Handling
20
Magnetic Resonance Spectroscopy
18
fludarabine
14
Prednisone
14
Vincristine
11
Doxorubicin
11
obinutuzumab
10
Lenalidomide
10
Etoposide
10
Bendamustine Hydrochloride
9
venetoclax
7
pembrolizumab
7
glofitamab
6
fludarabine phosphate
6
X-Rays
6
Tacrolimus
6
Nuclear Medicine Department, Hospital
6
Dexamethasone
6
Bortezomib
6
trametinib
5
ibrutinib
5
acalabrutinib
5
Mycophenolic Acid
5
Gemcitabine
5
Crizotinib
5
Busulfan
5
copanlisib
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
90 days
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled